ARTICLE | Company News
Iksuda to use Femtogenix's payloads in lead cancer ADC
March 8, 2019 5:30 PM UTC
Iksuda gained an exclusive license to incorporate Femtogenix's payload molecules into its lead antibody-drug conjugate (ADC) program for difficult-to-treat solid tumors. The payloads comprise pyridinobenzodiazepines (PDDs), which are enzymes that mono-alkylate DNA at specific target sequences.
A spokesperson for Femtogenix Ltd. (London, U.K.) and Iksuda Therapeutics (Newcastle upon Tyne, U.K.) told BioCentury that Iksuda plans to submit an IND for its lead product in 3Q20. Targets and financial terms are undisclosed...